ALC

Molina Healthcare, Inc. MOH is set to report its second-quarter 2026 results on July 22, after the closing bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $1.37 per share on revenues of $10.9 billion. The second-quarter earnings estimate remained stable over the past 60 days. The bottom-line projection indicates a year-over-year decrease of 75%. The Zacks Consensus Estimate for quarterly revenues suggests a year-over-year decline of 4.8%. Image Source: Zacks Investment Research For the current year, the Zacks Consensus Estimate for Molina Healthcare’s revenues is pegged at $44.4 billion, implying a fall of 2.2% year over year. Also, the consensus mark for current-year EPS is pegged at $5.23 per share, indicating a 52.6% year-over-year decline. MOH missed the consensus estimate for earnings in three of the last four quarters and beat once, with the average surprise being negative 186%. Molina Healthcare, Inc price-eps-surprise | Molina Healthcare, Inc Quote Our proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, that’s not the case here. MOH currently has an Earnings ESP of 0.00% and a Zacks Rank #3. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. The Zacks Consensus Estimate for MOH’s second-quarter premium revenues from Medicaid business indicates a 1.6% increase from the prior-year quarter’s reported figure, whereas our model predicts 4.5% growth. Similarly, the consensus mark for premium revenues from the Medicare unit signals a 1.2% increase from a year ago. The consensus mark for the Marketplace’s Medical Care Ratio (MCR) is pegged at 84.89% for the to-be-reported quarter, improving from 85.40% a year ago. Our model estimate for total operating expenses indicates a 0.8% year-over-year decline. However, the consensus mark for premium revenues from the Marketplace business implies a 46.4% decrease from the year-ago quarter. The consensus mark for Molina Healthcare’s total membership is pegged at 5 million, indicating a decline from 5.8 million a year ago. Meanwhile, the consensus mark for Medicare’s MCR is pegged at 93.69% for the to-be-reported quarter, deteriorating...

Intuitive Surgical, Inc. ISRG reported second-quarter 2026 adjusted earnings per share (EPS) of $2.80, which beat the Zacks Consensus Estimate of $2.48 by 12.9%. The bottom line increased 27.9% from $2.19 in the year-ago quarter. GAAP EPS was $2.28 versus $1.92 a year ago. Revenues rose 18.5% year over year to $2.89 billion and surpassed the consensus estimate of $2.81 billion by 3.1%. Growth reflected higher procedure volumes, system leasing revenues and expansion of the installed base. Worldwide da Vinci and Ion procedures increased about 16%. Recurring revenues reached $2.47 billion and represented about 85% of total quarterly revenues, highlighting the importance of procedure-driven instruments, accessories, leasing and service sales. Despite this robust quarterly performance, the stock was down 10.8% during after-hours trading on July 16, likely due to weaker sequential procedure growth. Intuitive Surgical, Inc. price-consensus-eps-surprise-chart | Intuitive Surgical, Inc. Quote ISRG’s Instruments Revenues Rise 18% Instruments and accessories revenues increased 17.7% year over year to $1.73 billion. Growth was driven by higher da Vinci and Ion procedure volumes, along with a favorable mix of da Vinci 5 and single-port procedures. Worldwide da Vinci procedure volume increased roughly 15% year over year, while Ion procedures climbed approximately 36%. U.S. da Vinci procedures rose 12%, led by general surgery, while procedures outside the United States advanced 20%. Management noted some moderation in deferrable U.S. procedures, partly reflecting patient coverage and premium dynamics. Bariatric procedures also declined in the high-single digits amid increased use of GLP-1 obesity drugs. International growth remained strong, particularly in India, Italy, Taiwan and the United Kingdom. Da Vinci instruments and accessories revenue per procedure was approximately $1,830, up from $1,800 a year earlier. Higher adoption of Force Feedback instruments and newer platforms supported the metric, while customer ordering patterns, increased cholecystectomy procedures and lower bariatric volumes limited growth. ISRG System Placements Gain on da Vinci 5 Systems revenues totaled $685 million, up 19.2% from the prior-year quarter’s level. Intuitive Surgical placed 468 da Vinci systems, an 18.5% increase from 395 systems a year ago. The total included 246 da Vinci 5 systems...

Thermo Fisher Scientific TMO is set to release second-quarter 2026 results on July 23, before the market opens. In the last reported quarter, the company posted adjusted earnings per share (EPS) of $5.44, which surpassed the Zacks Consensus Estimate by 4.62%. The company’s earnings topped estimates in each of the trailing four quarters, the average surprise being 3.69%. The Zacks Consensus Estimate for revenues is pegged at $11.68 billion, indicating an increase of 7.6% from the year-ago reported figure. The consensus mark for the company’s EPS implies a 6.5% year-over-year rise to $5.71. The estimate has dropped 1 cent in the past 30 days. The segment’s performance is expected to have benefited from continued strength in the Bioproduction business, driven by healthy demand from the pharma and biotech customers. Thermo Fisher further enhanced its Bioproduction offerings through the acquisition of Solventum’s Filtration and Separation business, adding advanced filtration technologies and industrial filtration and membrane solutions. Integration of this business is likely to have continued during the quarter. A steady cadence of product launches is also expected to have supported the Life Sciences Solutions segment. Among its newer innovations, Thermo Fisher introduced the Gibco CTS Compleo Fill and Finish System to help address manual fill and finish challenges in cell therapy manufacturing. The company also launched an integrated platform to advance scalable cell therapy manufacturing and introduced the Gibco CHOvantage GS Cell Line Development (“CLD”) Kit to help biologics developers accelerate time to clinic while maintaining regulatory confidence and commercial scalability. Thermo Fisher’s new Applied Biosystems PowerFlex Thermal Cycler is designed to help deliver enhanced flexibility, precise thermal performance and improved productivity for modern molecular biology laboratories. We expect all these developments to have positively boosted revenues in the second quarter of 2026. Per the Zacks Consensus Estimate, the Life Sciences Solutions revenues are expected to increase 9.6% year over year. The segment is likely to have continued to witness soft demand for instruments from academic and government customers in the United States and China. Tariffs and lower volumes may have also weighed on profitability. Despite this, Thermo Fisher’s strength in innovati...

Elevance Health, Inc. ELV is set to report its second-quarter 2026 results on July 15, 2026, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $6.18 per shareon revenues of $48.45 billion. The second-quarter earnings estimate witnessed one downward revision and no upward revisions over the past 60 days. The bottom-line projection indicates a year-over-year decline of 30.1%. Also, the Zacks Consensus Estimate for quarterly revenues implies a year-over-year decrease of 2%. Image Source: Zacks Investment Research For 2026, the Zacks Consensus Estimate for Elevance’s revenues is pegged at $194.24 billion, implying a fall of 1.7% year over year. The consensus mark for 2026 EPS is pegged at $26.86, indicating an 11.3% year-over-year decrease. Elevance’s earnings beat the consensus estimate in three of the trailing four quarters and missed once, with the average surprise being 10.6%. This is depicted in the figure below. Elevance Health, Inc. price-eps-surprise | Elevance Health, Inc. Quote Our proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here. ELV currently has an Earnings ESP of -0.42% and a Zacks Rank #2. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. The Zacks Consensus Estimate for product revenues indicates 4.7% growth from the year-ago period’s $6.04 billion. However, the consensus estimate for premiums indicates a 3.3% decrease from the year-ago period. The consensus mark for Commercial Individual membership implies 10% fall from a year ago, while our model estimate indicates a 12.2% decline. Also, declining memberships in Medicaid (-5.8%) are likely to have kept second-quarter performance in check. However, the consensus estimate for Commercial Fee-based memberships indicates 1.9% year-over-year growth. Meanwhile, the Zacks Consensus Estimate for Carelon brand’s operating income for the second quarter indicates a 3.8% year-over-year decrease. The consensus estimate for the Health Benefits segment’s operating income for the second quarter indicates a 34.7% year-over-year plunge, making an earnings beat uncertain. The Zacks Consensus...

ALISO VIEJO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced select preliminary financial results for the second quarter of 2026 and updates to its standalone product pipeline, following the announcement of the company’s strategic collaboration with Alcon to develop and commercialize light-adjustable Presbyopia-Correcting Intraocular Lenses. Preliminary Second Quarter 2026 Results Total company revenue is expected to be approximately $32 to $34 million, which includes, Sales of approximately $27 million, which includes, Cash, cash equivalents and short-term investments of approximately $209 million as of June 30, 2026. Pipeline Highlights Next-generation RxSight Light Adjustable Technology™ platform, with intermediate-term launches of new LAL®, LAL +®, and LAL Toric lenses with improved workflow and fewer required post-operative treatments. Collaboration with Alcon to innovate our respective platforms to develop and commercialize light-adjustable Presbyopia-Correcting Intraocular Lenses (Simultaneous Vision Intraocular Lenses). “While we faced meaningful commercial headwinds in Q2, including from more widespread competitive trialing, the unique ability of RxSight’s Light Adjustable Technology to customize visual outcomes continued to deliver significant clinical benefits to thousands of patients around the world,” said Dr. Ron Kurtz, Chief Executive Officer and President of RxSight. “To position the company for deeper penetration of current, next-generation, and collaboration products, we are accelerating investments in our LAL sales force and commercial capabilities, while maintaining a disciplined approach to overall spending. By leveraging our differentiated technology, large customer base, strong balance sheet and exciting pipeline, we believe RxSight is well positioned to drive both high-margin implant sales and future royalty income, thereby empowering doctors to deliver the industry’s premier outcomes for even more of their patients.” Updated Product Pipeline RxSight is developing the first and only suite of adjustable IOLs built on its next-generation Light Adjustable Lens technology platform with improved workflow and enhanced performance. Highlights include: Next-generation LAL, designed to deliver best-in-class visual quality and optical clarity, with post-operative refractive optimization to consistently ach...

National Vision Holdings, Inc. EYE posted first-quarter 2026 adjusted earnings of 45 cents per share, up 32.4% year over year. The bottom line beat the Zacks Consensus Estimate by 4.7%. Quarterly net revenues were $543.9 million, up 6.6% from the year-ago period’s level. The figure beat the Zacks Consensus Estimate by about 0.2%. Higher average ticket and continued strength in the managed care cohort helped drive adjusted comparable store sales growth of 4.5% in the quarter. EYE’s top-line growth can be attributed to a combination of underlying demand and accounting timing. Revenue growth was driven by stronger results in its core business and a positive 2.0% impact from the timing of unearned revenues. Within the Owned & Host segment, performance was positive across key banners. America’s Best comparable sales rose 4.4% year over year, while Eyeglass World comparable sales improved 5.2%. Other channels also contributed. Military comparable sales increased 2.2% and the Fred Meyer host business posted 4.7% growth, pointing to solid execution across formats. On a consolidated basis, gross profit in the first quarter increased 6.4% year over year to $324.7 million, driven by higher revenues of $543.9 million. Gross margin was 59.7%, edging down about 8 bps from the prior-year quarter’s level, as costs applicable to revenues rose 6.8% to $219.1 million. SG&A expenses rose 0.2% marginally to $256.1 million. Operating income climbed to $45.2 million, translating into an operating margin of 8.3%, which expanded roughly 320 bps year over year. National Vision ended the first quarter of 2026 with cash and cash equivalents of $67.9 million compared with $38.7 million in the fourth quarter of 2025. Net cash provided by operating activities for the quarter totaled $61.7 million compared with $32.2 million in the prior-year period. National Vision Holdings, Inc. price-consensus-eps-surprise-chart | National Vision Holdings, Inc. Quote For 2026, net revenues are projected to be in the range of $2.03-$2.09 billion. The Zacks Consensus Estimate for the metric is currently pegged at $2.06 billion. Adjusted EPS is estimated to be between 85 cents and $1.09. The Zacks Consensus Estimate is currently pegged at 94 cents. National Vision ended the first quarter of 2026 with better-than-expected earnings and revenues. EYE continued to reshape its footprint while still adding units...

Prestige Consumer Healthcare Inc. PBH posted fourth-quarter fiscal 2026 adjusted diluted earnings per share (EPS) of $1.23, down 6.8% from $1.32 a year ago. The figure missed the Zacks Consensus Estimate by 11.7%. GAAP EPS was $1.13 compared with $1.00 a year ago. For fiscal 2026, adjusted EPS was $4.38 compared with $4.52 in the previous year. Quarterly revenues totaled $281.6 million, down 5.0% year over year. The figure fell short of the Zacks Consensus Estimate by 4.3%. For fiscal 2026, the company generated total revenues of $1.09 billion, down 4.3% from the prior-year figure. North American OTC Healthcare’s revenues amounted to $234.5 million for the fiscal fourth quarter, down 5.8% year over year. The decrease was primarily due to lower Eye & Ear Care category sales caused by the limited ability to meet demand for Clear Eyes. International OTC Healthcare’s revenues totaled $47.1 million in the fiscal fourth quarter, down 1% year over year. The weaker revenue performance can be attributed to shipping disruptions in the Middle East and lower sales in the Eye & Ear Care category. The gross profit in the fiscal fourth quarter fell 13.9% year over year to $146.3 million. The gross margin contracted 539 basis points (bps) year over year to 51.9% due to a 6.5% increase in the cost of sales (excluding depreciation). During the quarter, advertising and marketing expenses declined 5.2% to $35.1 million, while general and administrative expenses increased 11.9% to $30.3 million. Operating income, excluding depreciation and amortization, totaled $80.9 million, reflecting a 13.4% decrease. The adjusted operating margin contracted 279 bps to 28.7%. Prestige Consumer exited the fiscal fourth quarter of 2026 with cash and cash equivalents of $63.9 million compared with $97.9 million a year ago. Prestige Consumer generated net cash provided by operating activities of $257.6 million in fiscal 2026, up from $251.5 million in the prior year. PBH revealed its fiscal 2027 outlook, projecting revenues in the range of $1.10-$1.12 billion and organic revenue growth in the band of 1-3%. The Zacks Consensus Estimate for revenues is currently pegged at $1.10 billion. The company expects adjusted diluted earnings per share between $4.42 and $4.51. The Zacks Consensus Estimate was pegged at $4.54 for the metric. Prestige Consumer Healthcare Inc. price-consensus-eps-surprise-chart...

STERIS plc STE posted fourth-quarter fiscal 2026 adjusted earnings of $2.83 per share, up 3.3% year over year. The bottom line missed the Zacks Consensus Estimate by 0.9%. On a GAAP basis, earnings per share (EPS) were $2.24 compared with $1.48 cents in the prior-year quarter. HAE posted adjusted earnings per share of $10.17 for fiscal 2026, up from $9.22 in fiscal 2025. Total revenues from continuing operations rose 7.3% to $1.59 billion but lagged the Zacks Consensus Estimate of $1.60 billion by 0.5%. Organic revenues at constant exchange rate or CER rose 5% year over year. For fiscal 2026, the company generated total revenues of $5.94 billion, up 8.8% from the prior-year figure. Following the earnings announcement, STE stock fell 0.9% in after-market trading yesterday. The decline was likely due to investor concerns over the company’s modest top and bottom-line misses. Healthcare remained the primary growth engine. Segment revenues increased 7% year over year to $1.14 billion, reflecting a 9% improvement in service revenues, 7% growth in consumable revenues and a 6% increase in capital equipment revenues. Applied Sterilization Technologies (“AST”) also advanced, with revenues up 6% to $289.2 million, reflecting 10% growth in service revenues and a 62% decline in capital equipment revenues. Life Sciences posted the fastest percentage growth, rising 9% to $162.9 million, supported by 19% growth in capital equipment, an 8% rise in service revenues and a 5% improvement in consumable revenues. Gross profit increased to $697.1 million from $641.2 million in the prior-year quarter. Gross margin expanded 57 basis points (bps) year over year to 43.9%, despite a 6.2% rise in cost of revenues. Selling, general and administrative expenses increased 5.4% to $351.8 million and research and development expenses rose 4% to $28.8 million. Total operating expenses declined to $380.3 million, aided by the absence of the Illinois EO litigation settlement recorded in the prior-year quarter and a restructuring credit in the current period. The adjusted operating margin contracted 61 bps to 24.2%. STERIS plc price-consensus-eps-surprise-chart | STERIS plc Quote STERIS ended fiscal 2026 with a significantly higher cash position. Cash and cash equivalents totaled $439.6 million compared with $171.7 million a year ago, providing added flexibility for shareholder returns and reinve...

Haemonetics Corporation HAE delivered fourth-quarter fiscal 2026 adjusted earnings of $1.29 per share, up 4.0% year over year. The figure beat the Zacks Consensus Estimate by 1.0%. On a GAAP basis, loss per share was 44 cents compared to earnings of of $1.17 per share in the prior-year quarter. HAE posted adjusted earnings per share of $4.96 for fiscal 2026, up from $4.57 in fiscal 2025. Revenues rose 4.8% from the year-ago period’s level to $346.35 million, topping the Zacks Consensus Estimate by 2.4%. For fiscal 2026, the company generated total revenues of $1.33 billion, down 2.0% from the prior-year figure. Strength across the company’s core platforms stood out, with organic revenue growth of 4.5% and organic growth excluding CSL impacts of 8.6%, helping offset continued softness in interventional technologies. Following the earnings announcement, HAE’s shares rose 1.4% last Friday. At Plasma, revenues totaled $130.3 million, up 2.8% year over year (up 1.8% on an organic basis). Organic growth, excluding CSL impacts, was 12.7%, reflecting continued momentum in the franchise. Revenues at Blood Center increased 0.7% to $56.4 million (up 5.5% on an organic basis). The segment’s organic performance reflected the benefit of portfolio-adjusted growth. Hospital revenues rose 8.0% to $159.6 million (up 6.5% organically). In the fourth quarter of fiscal 2026, gross profit increased 2.7% to $198.2 million. Gross margin contracted 120 basis points (bps) year over year to 57.2% as cost of goods sold rose 7.7% to $148.1 million. Selling, general and administrative expenses increased 5.6% to $121.8 million, while research and development expenses declined 9.2% to $14.4 million. Total operating expenses jumped 81.8% to $221.2 million, driving an operating loss of $23.0 million compared to operating income of $71.3 million in the prior-year quarter. Haemonetics ended fiscal 2026 with $245.4 million in cash and cash equivalents compared to $306.8 million at the end of fiscal 2025. Cumulative net cash flow at the end of fiscal fourth-quarter 2026 was $293.2 million compared with $181.7 million a year ago. Haemonetics Corporation price-consensus-eps-surprise-chart | Haemonetics Corporation Quote Management expects reported revenue growth of 4-7%, including an estimated 53rd-week impact of roughly 2% and a currency impact of 0-1%. Organic revenue growth is projected at 3-6%...

7 ALLY Robotic Cataract Laser Systems® (“ALLY System”) Placements in First Quarter 2026; Backlog of 11 ALLY Systems as of March 31, 2026 First Quarter Recurring Revenue was $12.6 million Total Laser Installed Base Climbs to 440 Systems, Driven by 39% Growth in ALLY Placements ORLANDO, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2026 and provided an update on key operational initiatives. “Our first quarter total revenue and related system placement results decreased slightly as compared to the first quarter of 2025, primarily driven by the uncertainty and disruption in the market around the Alcon transaction, which was terminated near the end of the quarter. Despite the effect of the lengthy transaction process and uncertainty in the outcome of the acquisition, which have had a significant impact on system placements, the underlying fundamentals of our business remain strong. The core business in recurring revenue is solid and our outlook is one of continued growth,” said Nick Curtis, President and CEO of LENSAR. “Notably, our recurring revenue reached approximately $12.6 million in the first quarter, representing approximately 94% of our total revenue. There is no question the value ALLY brings to surgeons. We expect recurring revenue will continue to grow as utilization ramps and we return to historical levels of system placements over the next several quarters, now that the merger-related uncertainty is in the rear view mirror.” First Quarter 2026 Financial Results Total revenue for the quarter ended March 31, 2026 was $13.4 million, reflecting a decrease of 5% compared to total revenue of $14.2 million for the quarter ended March 31, 2025. The decrease was primarily attributable to decreased systems sales of $1.8 million partially offset by increased procedure volume of $1.0 million. First quarter 2026 recurring revenue increased approximately $1.1 million, or 9%, over the first quarter of 2025. During the three months ended March 31, 2026, the Company placed 7 ALLY Systems, bringing the total installed ALLY base to approximately 205 at quarter end. As of March 31, 2026 the Company had a backlog of 11 ALLY Systems pending install...

Globus Medical, Inc. GMED delivered first-quarter 2026 adjusted earnings of $1.12 per share, up 64.7% year over year. The figure beat the Zacks Consensus Estimate by 22.1%. Revenues climbed 27.0% year over year to $759.9 million and topped the Zacks Consensus Estimate by 4.0%. Following the earnings announcement, GMED stock rose 5.8% in the after-market trading yesterday. The company’s geographic performance showed solid demand across markets. Sales in the United States rose 25% year over year to $604.9 million, supported by continued strength in core spine and contributions from other domestic businesses. International net sales increased 35.6% year over year to $155.0 million. On a constant-currency basis, international sales grew 27.8%, with currency contributing $9.0 million to the reported international revenue line, underscoring a favorable FX backdrop during the quarter. Musculoskeletal Solutions revenues of $733.0 million, up 27.3% year over year. Enabling Technologies generated $26.9 million in sales, up 21.1% from the prior-year quarter’s level, reflecting strong performance against a softer prior year. The gross profit in the reported quarter increased 32.7% year over year to $504.7 million. Gross margin expanded 280 basis points (bps) to 66.4%, aided by higher sales and improved cost efficiency. Cost of sales (exclusive of amortization of intangibles) rose 19.8% to $234.1 million. In terms of operating expense, SG&A expenses rose 22.7% year over year to $297.8 million, while research and development spending increased 10.4% to $36.5 million. Operating income climbed 55.0% to $150.4 million and operating margin improved 358 bps to 19.8%, reflecting solid operating leverage despite higher spending levels. GMED ended the first quarter with total cash, cash equivalents and marketable securities of $799.3 million, up from $629.1 million at the end of 2025, reflecting strong cash generation and balance-sheet flexibility. Globus Medical, Inc. price-consensus-eps-surprise-chart | Globus Medical, Inc. Quote Net cash provided by operating activities was $202.4 million compared with the year-ago figure of $177.3 million. For full-year 2026, the company reaffirmed revenue guidance of $3.18-$3.22 billion, signaling confidence in its top-line plan despite timing and mix variability across certain businesses. The Zacks Consensus Estimate is currently pegged at...

Sight Sciences reported a “strong start” to 2026 with total Q1 revenue of $19.7 million, up 13% year-over-year, gross margin of 86%, a narrower net loss of $13.0 million, and cash of $85 million while quarterly cash usage fell to $7 million. Interventional Dry Eye revenue nearly doubled sequentially to $1.4 million driven by ~1,500 SmartLids sold (vs. ~700 in Q4), prompting management to raise dry eye guidance and project $6–8 million for the full year. Management raised full-year revenue guidance to $83–$89 million and kept adjusted operating expense guidance of $93–$96 million, while a court upheld a ~ $55 million past-damages judgment (plus ongoing royalties) in patent litigation with Alcon that is subject to appeal and not yet collected; the company says it is positioned to reach cash-flow breakeven without raising equity. Interested in Sight Sciences, Inc.? Here are five stocks we like better. Sight Sciences (NASDAQ:SGHT) reported first-quarter 2026 results that management said marked a “strong start” to the year, highlighted by a return to double-digit revenue growth, steady gross margin performance, and lower cash usage. The company also raised its full-year 2026 revenue guidance while maintaining its adjusted operating expense outlook. Co-Founder and CEO Paul Badawi said the company delivered “a strong start to 2026” with results reflecting “a return to double-digit revenue growth, continued strength in gross margin, and disciplined operating expense and cash management.” → Berkshire Hathaway’s Record Cash Hoard: Why and What's Next? CFO Jim Rodberg reported total revenue of $19.7 million in the first quarter, up 13% year over year, “driven by growth in each of our two Interventional segments.” Gross margin was 86%, flat compared to the prior-year period. Interventional Glaucoma (OMNI): Revenue of $18.3 million, up 7% year over year. Interventional Dry Eye (TearCare): Revenue of $1.4 million, up from $0.4 million in the prior-year period and “nearly doubling” from the fourth quarter of 2025. Rodberg said net loss was $13.0 million, or $0.24 per share, compared with a net loss of $14.2 million, or $0.28 per share, in the year-ago quarter. The company ended the quarter with $85 million in cash and cash equivalents, down from $92 million at the end of 2025, and reported $7 million of cash used in the quarter versus $11.6 million in the first quarter of...